NCT06024057View on ClinicalTrials.gov

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

NANot yet recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2038

Conditions
To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
Interventions
DRUG

LX101

LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT06024057 - An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA | Biotech Hunter | Biotech Hunter